Daclizumab + Mycophenolate mofetil (MMF) + Prednisone + Tacrolimus + Ganciclovir + Valganciclovir + Trimethoprim and sulfamethoxazole
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Diseases
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Trial Timeline
Mar 1, 2004 → Nov 1, 2010
NCT ID
NCT00141037About Daclizumab + Mycophenolate mofetil (MMF) + Prednisone + Tacrolimus + Ganciclovir + Valganciclovir + Trimethoprim and sulfamethoxazole
Daclizumab + Mycophenolate mofetil (MMF) + Prednisone + Tacrolimus + Ganciclovir + Valganciclovir + Trimethoprim and sulfamethoxazole is a phase 1/2 stage product being developed by Astellas Pharma for Kidney Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00141037. Target conditions include Kidney Diseases, Kidney Transplantation, Kidney Transplant.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Diseases were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00141037 | Phase 1/2 | Completed |
Competing Products
20 competing products in Kidney Diseases